Peritoneal metastases represent a challenging situation where cancer from organs like the stomach, ovaries, or colon spreads to the membrane lining the abdominal cavity. While this advanced stage once meant very limited options, today’s treatment landscape includes specialized surgical techniques combined with heated chemotherapy, alongside newer approaches being tested in clinical trials to help patients live longer and maintain better quality of life.

Understanding Treatment Goals and Possibilities

When cancer spreads to the peritoneum—the thin membrane lining the abdomen and covering internal organs—the treatment approach becomes highly individualized. The peritoneum normally supports abdominal organs and contains blood vessels and nerves that supply them. When cancer cells reach this membrane from other organs, it typically signals advanced disease, often classified as Stage IV^[1].

Treatment goals vary depending on how far the cancer has spread throughout the peritoneal cavity, which organs were originally affected, and the patient’s overall health. For some patients, treatment aims to control symptoms such as abdominal swelling, pain, and bowel obstruction. For others, more aggressive approaches seek to slow disease progression significantly or even achieve long-term disease control. The treatment depends heavily on factors like the extent of peritoneal involvement, the type of original cancer, and whether all visible tumors can be surgically removed^[2].

Medical teams use specialized tools to plan treatment. One such tool is the Peritoneal Carcinomatosis Index, which maps tumor locations throughout the abdomen and small intestine, assigning scores based on tumor size. This scoring system helps doctors determine whether surgery is likely to successfully remove all visible disease^[2].

Not all patients with peritoneal metastases are candidates for the same treatments. Those with cancer primarily originating in the ovaries, colon, stomach, appendix, or pancreas may have different treatment options available. In about 10 percent of cases, cancer reaches the peritoneum from organs outside the abdominal cavity, traveling through the bloodstream or lymphatic system^[2].

Standard Treatment Approaches

The cornerstone of standard treatment for peritoneal metastases combines two major components: cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, commonly known as HIPEC. This combined approach has transformed outcomes for many patients who previously had few treatment options^[2].

Cytoreductive surgery involves removing all visible tumor tissue from the peritoneal surfaces. Surgeons meticulously examine the entire abdominal cavity, removing tumor deposits from the peritoneum itself and from affected portions of organs. The goal is to achieve complete removal of all visible disease, leaving only microscopic cancer cells that can then be targeted with chemotherapy. This surgery can be extensive, sometimes lasting many hours, as surgeons work to eliminate every visible tumor nodule^[9].

HIPEC follows immediately after cytoreductive surgery, while the patient is still in the operating room. During this procedure, heated chemotherapy solution is circulated throughout the abdominal cavity for a specific period, typically 60 to 90 minutes. The heat enhances the chemotherapy’s ability to penetrate and destroy remaining microscopic cancer cells. The temperature of the chemotherapy solution is carefully controlled, usually maintained between 41 and 43 degrees Celsius. This heating effect damages cancer cells more than normal cells, while the direct delivery into the abdomen allows much higher drug concentrations than would be safe with systemic chemotherapy^[2].

The specific chemotherapy drugs used during HIPEC depend on the type of original cancer. Common agents include mitomycin C, cisplatin, or oxaliplatin. These drugs work by damaging cancer cell DNA or interfering with cell division processes. Because the chemotherapy is delivered directly into the abdominal cavity rather than through the bloodstream, the concentration reaching peritoneal surfaces is much higher while systemic side effects can be reduced^[9].

Recovery from cytoreductive surgery with HIPEC typically requires significant time. Patients often remain hospitalized for one to three weeks, depending on the extent of surgery and any complications. Common side effects include fatigue, abdominal discomfort, and temporary changes in bowel function. Some patients experience fluid accumulation in the abdomen that may require drainage. More serious complications can include infection, bleeding, or problems with wound healing^[9].

For patients who are not candidates for cytoreductive surgery with HIPEC, standard systemic chemotherapy remains an important treatment option. These chemotherapy regimens are given intravenously and circulate throughout the body. The specific drugs chosen depend on the type of original cancer. While systemic chemotherapy may not eliminate peritoneal metastases, it can help control disease growth, reduce symptoms, and improve quality of life^[2].

Managing symptoms is a crucial component of standard care. When peritoneal metastases cause fluid buildup in the abdomen—a condition called ascites—patients may undergo paracentesis, a procedure where excess fluid is drained using a needle inserted through the abdominal wall. This provides relief from abdominal swelling, discomfort, and breathing difficulties. Some patients require repeated drainage procedures as fluid reaccumulates^[2].

Bowel obstructions, another common complication of peritoneal metastases, may require various interventions. These range from dietary modifications and medications that reduce intestinal secretions to surgical procedures that bypass blocked segments of intestine. Pain management is also essential, often requiring a combination of medications including non-opioid pain relievers, opioids for severe pain, and medications that target nerve-related pain^[4].

Innovative Treatment Approaches in Clinical Trials

Beyond standard treatments, researchers are actively investigating new approaches for treating peritoneal metastases through clinical trials. These studies explore whether innovative therapies can improve outcomes for patients, offering hope for those whose disease does not respond adequately to existing treatments.

One promising area of investigation involves Pressurized Intraperitoneal Aerosol Chemotherapy, known as PIPAC. This technique delivers chemotherapy as a pressurized aerosol directly into the abdominal cavity during a minimally invasive laparoscopic procedure. The pressure helps the chemotherapy penetrate deeper into peritoneal surfaces and tumor tissue. Unlike HIPEC, PIPAC can be repeated multiple times because it’s less invasive. Early studies suggest this approach may benefit patients whose peritoneal metastases cannot be completely removed surgically^[10].

Clinical trials are also examining whether combining PIPAC with systemic chemotherapy provides better disease control than either treatment alone. The aerosol delivery system allows drugs to reach areas of the peritoneum that might be difficult to access with liquid chemotherapy solutions. Patients in these trials typically receive PIPAC treatments every few weeks, with the exact schedule depending on the specific study protocol.

Another area of active research focuses on immunotherapy approaches for peritoneal metastases. Immunotherapy works by helping the body’s immune system recognize and attack cancer cells. Some clinical trials are testing immune checkpoint inhibitors—drugs that remove brakes on the immune system—specifically for peritoneal metastases. These medications, which include drugs targeting proteins called PD-1 and PD-L1, have shown promise in other cancer settings and are now being evaluated for peritoneal disease^[3].

Researchers are also investigating targeted therapies that attack specific molecular pathways involved in peritoneal metastases development. These drugs are designed to interfere with particular proteins or genetic mutations that cancer cells need to grow and spread. Some trials examine whether adding targeted therapies to standard chemotherapy improves outcomes. Others test whether these drugs can help patients whose disease has progressed despite previous treatments.

Clinical trials testing new drug combinations are exploring whether delivering multiple chemotherapy agents during HIPEC provides better cancer control than single-agent treatment. These studies carefully monitor patients for side effects while evaluating whether the additional drugs improve survival or time until disease progression. The goal is finding the optimal balance between treatment effectiveness and manageable side effects.

Some research centers are conducting trials of second-look surgery for certain patients. This approach involves planned surgery after initial chemotherapy to remove any remaining peritoneal disease that might not have been detected earlier. Second-look procedures may be combined with intraperitoneal chemotherapy to target microscopic disease. These trials typically enroll patients whose imaging studies show good response to initial treatment but who remain at high risk for disease recurrence^[15].

Early-phase clinical trials (Phase I and Phase II) are testing entirely new molecules and treatment approaches that haven’t yet been widely studied in peritoneal metastases. Phase I trials primarily assess safety and determine appropriate dosing, while Phase II trials begin evaluating whether the treatment shows promise for controlling disease. Patients participating in these early trials often have exhausted standard treatment options and are seeking experimental approaches.

Clinical trials investigating peritoneal metastases treatments are conducted at specialized centers in many countries, including the United States, Europe, and Asia. Eligibility requirements vary by study but typically consider factors like the extent of peritoneal disease, type of original cancer, previous treatments received, and overall health status. Patients interested in clinical trials should discuss options with their oncology team, as not every trial is appropriate for every patient^[3].

Most common treatment methods

• Cytoreductive Surgery
  • Surgical removal of all visible tumor tissue from peritoneal surfaces and affected organs
  • Goal is achieving complete removal of visible disease to allow chemotherapy to target remaining microscopic cancer cells
  • Often combined with HIPEC during the same operative procedure
• HIPEC (Hyperthermic Intraperitoneal Chemotherapy)
  • Heated chemotherapy solution circulated throughout abdominal cavity immediately after cytoreductive surgery
  • Temperature typically maintained between 41-43 degrees Celsius to enhance cancer cell destruction
  • Duration usually 60-90 minutes with drugs like mitomycin C, cisplatin, or oxaliplatin
  • Direct delivery allows much higher drug concentrations at peritoneal surfaces than systemic chemotherapy
• PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy)
  • Chemotherapy delivered as pressurized aerosol into abdominal cavity during minimally invasive laparoscopic procedure
  • Can be repeated multiple times due to less invasive nature
  • May benefit patients whose disease cannot be completely removed surgically
  • Currently being studied in clinical trials
• Systemic Chemotherapy
  • Chemotherapy given intravenously that circulates throughout the body
  • Specific drugs chosen based on type of original cancer
  • May help control disease growth and reduce symptoms when surgery is not an option
• Symptom Management Procedures
  • Paracentesis for draining excess abdominal fluid (ascites) to relieve swelling and breathing difficulties
  • Interventions for bowel obstructions including dietary changes, medications, or surgical bypass procedures
  • Pain management using combinations of medications
• Immunotherapy
  • Treatments that help the immune system recognize and attack cancer cells
  • Includes immune checkpoint inhibitors targeting proteins like PD-1 and PD-L1
  • Currently being tested in clinical trials for peritoneal metastases